Are you Dr. Nasim?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 31 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
600 Gresham Drive,
Dept Of Pathology
Norfolk, VA 23507Phone+1 757-388-3488Fax+1 757-388-3799
Summary
- Dr. Suhail Nasim, MD is a board certified pathologist in Norfolk, Virginia. He is currently licensed to practice medicine in Virginia and North Carolina. He is affiliated with Sentara Norfolk General Hospital, Sentara Leigh Hospital, and Sentara CarePlex Hospital.
Education & Training
- Virginia Commonwealth University Health SystemResidency, Pathology-Anatomic and Clinical, 1993 - 1997
- George Washington University School of MedicineInternship, Transitional Year, 1992 - 1993
- Allama Iqbal Medical CollegeClass of 1982
Certifications & Licensure
- VA State Medical License 1997 - 2026
- NC State Medical License 2016 - 2025
- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Molecular Genetic Pathology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Publications & Presentations
PubMed
- 85 citationsEvaluation of Quality-Control Criteria for Microarray Gene Expression AnalysisCatherine I. Dumur, Suhail Nasim, Al M. Best, Kellie J. Archer, Amy C. Ladd
Clinical Chemistry. 2004-11-01 - 27 citationsEvaluation of a linear amplification method for small samples used on high-density oligonucleotide microarray analysis.Catherine I. Dumur, Carleton T. Garrett, Kellie J. Archer, Suhail Nasim, David S. Wilkinson
Analytical Biochemistry. 2004-08-15 - 129 citationsNormal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spe...Lisa H. Cazares, Bao Ling Adam, Michael D. Ward, Suhail Nasim, Paul F. Schellhammer
Clinical Cancer Research. 2002-08-01